BIMATOPROST BROWN & BURK

Posology The recommended dose is one drop in the affected eye(s) once daily, administered in the evening. The dose should not exceed once daily as more frequent administration may lessen the intraocular pressure lowering effect. For single use only, one container is sufficient to treat both eyes.

Any unused solution should be discarded immediately after use. 3 mg/mL eye drops, solution, in single-dose container in children aged 0 to 18 years has not yet been established. 3 mg/mL eye drops, solution, in single-dose container has not been studied in patients with renal or moderate to severe hepatic impairment and should therefore be used with caution in such patients.

3 mg/mL eye drops (multi-dose formulation), solution had no adverse effect on liver function over 24 months. Method of administration If more than one topical ophthalmic medicinal product is being used, each one should be administered at least 5 minutes apart.

8 Table 2) and did not increase following 3 years treatment.

Adverse reactions reported in phosphate containing eye drops:

Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged corneas. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

3 mg/mL eye drops, solution, in single-dose container. 8). 3 mg/mL eye drops (multi-dose formulation). g. aphakic patients, pseudophakic patients with a torn posterior lens capsule). 3 mg/mL eye drops, solution (multi- dose formulation).

g. herpes simplex) or uveitis/iritis. 3 mg/mL eye drops, solution in single-dose container has not been studied in patients with inflammatory ocular conditions, neovascular, inflammatory, angle-closure glaucoma, congenital glaucoma or narrow-angle glaucoma.

3 mg/mL eye drops, solution, in single-dose container comes repeatedly in contact with the skin surface. 3 mg/mL eye drops, solution in single- dose container as instructed and avoid it running onto the cheek or other skin areas. 3 mg/mL eye drops, solution, in single-dose container has not been studied in patients with compromised respiratory function.

While there is limited information available on patients with a history of asthma or COPD, there have been reports of exacerbation of asthma, dyspnoea and COPD, as well as reports of asthma, in post marketing experience. The frequency of these symptoms is not known.

Patients with COPD, asthma or compromised respiratory function due to other conditions should be treated with caution. 3 mg/mL eye drops, solution, in single-dose container has not been studied in patients with heart block more severe than first degree or uncontrolled congestive heart failure.

3 mg/mL eye drops, solution (multi-dose formulation). 3 mg/mL eye drops, solution, in single-dose container should be used with caution in patients predisposed to low heart rate or low blood pressure. 3 mg/mL in patients with glaucoma or ocular hypertension, it has been shown that the more frequent exposure of the eye to more than one dose of bimatoprost daily may decrease the IOP-lowering effect.

3 mg/mL eye drops, solution, in single-dose container with other prostaglandin analogues should be monitored for changes to their intraocular pressure. 3 mg/mL eye drops, solution, in single-dose container has not been studied in patients wearing contact lenses.

Contact lenses should be removed prior to instillation and may be reinserted 15 minutes following administration. Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures, to avoid eye injury and contamination of the solution.

3 mg/ml , that is to say essentially ‘sodium-free’.

1.